Form 4: United Therapeutics EVP Sells Shares After Option Exercise

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and subsequently sold 11,000 shares of common stock under a pre-arranged 10b5-1 plan.

Summary

• Paul A. Mahon, Executive Vice President & General Counsel of United Therapeutics Corp (UTHR), reported changes in his beneficial ownership.
• On August 21, 2025, Mr. Mahon exercised 11,000 stock options at an exercise price of $135.42 per share.
• Concurrently, he sold all 11,000 shares of common stock acquired from the option exercise through multiple transactions.
• The sales were executed at weighted average prices ranging from $304.565 to $310.2485 per share.
• These transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan established on December 24, 2024.
• Following these transactions, Mr. Mahon directly beneficially owns 36,781 shares of common stock and 77,000 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-arranged insider transaction (option exercise and sale) under a 10b5-1 plan. This type of transaction is generally neutral in sentiment as it typically does not signal new material information about the company's prospects.

Positives

• The executive exercised stock options at a significantly lower price ($135.42) and sold the shares at a much higher market price (ranging from $304.565 to $310.2485), indicating a substantial personal gain.
• The transactions were executed under a pre-arranged 10b5-1 plan, which suggests the sales were scheduled and not based on new material non-public information.

Negatives

• The sale of shares by a high-ranking executive, even if pre-planned, represents a reduction in insider ownership.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The exercise of stock options and sale of resulting shares were executed pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024.

Industry Context

This filing is a routine insider transaction report and does not provide specific industry context or trends. It reflects an individual executive's compensation-related activity.

Stakeholder Impact

• Shareholders: The sale of shares by an executive could be perceived as a slight negative, but the pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling. The overall impact is likely minimal as it's a routine compensation event.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

The filing details a routine, pre-arranged insider transaction (option exercise and sale) under a 10b5-1 plan. This type of transaction typically does not signal new material information about the company's prospects and therefore does not warrant a change in investment recommendation based solely on this filing. Investors should continue to evaluate the company based on its fundamental performance and broader market conditions.

Keywords

United Therapeutics, UTHR, SEC Form 4, Insider Trading, Stock Option Exercise, Share Sale, Paul A. Mahon, 10b5-1 Plan, Executive Compensation